Author:
Y Chitra,Ch Urvashi,H Lokhendro,Ng Brajachand,Kh Sulochana,Singh Y Ibotomba
Publisher
Akshantala Enterprises Private Limited
Reference19 articles.
1. 1. MMWR. (1998) Guidelines for the use of anti-retroviral agents in HIV infected adults and adolescents. Department of Health and Human services and Henry J Kaiser Family Foundation, MMWR Recmm Rep; 47: 43-82.
2. 2. WHO. Treating 3 million by 2005, making it happen, The WHO Strategy. WHO 2003: http://www.who.int/3 by 5/publications/documents/en/3by 5 strategy making it happen.pdf. Accessed on March 18, 2005.
3. 3. Kovacs JA, Masur H (2003). Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. New England Journal of Medicine; 342:1416-1429.
4. 4. Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13: 1647-1651.
5. 5. Hogg RS, Yip B, Chan KJ ,Wood E, Craib KJP et al( 1999). Rates of Disease Progressive by Baseline Cd4 Cell count and viral load after Initiating Triple Drug Therapy, JAMA; 286(20): 2568-2577.